DCOY Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About DCOY Interactive Breakdown Better Bets vs. DCOY Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Decoy Therapeutics Inc. (DCOY)

    Market Price (9/14/2026): $2.63 | Market Cap: $1.4 MilSector: Health Care | Industry: Biotechnology

    Decoy Therapeutics Inc. (DCOY)

    Market Price (9/14/2026): $2.63
    Market Cap: $1.4 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -583%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Oncology Treatments, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -141%, 3Y Excs Rtn is -171%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -15 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1021%

    High stock price volatility
    Vol 12M is 156%

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -583%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Oncology Treatments, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -141%, 3Y Excs Rtn is -171%
    3 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    4 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -15 Mil
    5 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1021%
    6 High stock price volatility
    Vol 12M is 156%

    Valuation & Metrics

    FYE: 12/31DCOY [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$11.9 Mil—
    FY 2027 Sales$0.0 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth-100.0%13.0%
    EARNINGS
    LTM Net Income (GAAP) [3]$-14.4 Mil—
    FY 2026 Net Income (Non-GAAP)$-6.3 Mil—
    FY 2027 Net Income (Non-GAAP)$-9.3 Mil—
    FY 2027 Net Income Growth—18.3%
    FY 2026 EPS (Non-GAAP)$-13.01—
    FY 2027 EPS (Non-GAAP)$-19.32—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S0.11.6
    FY 2027 P/S——
    FY 2026 P/E—7.4
    FY 2027 P/E——

    [1] DCOY forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Lead Antiviral Program StatusPreclinical, advancing toward an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration.11142025Link
    Antiviral Program TargetsA broad pan-coronavirus therapeutic, and another antiviral targeting flu, COVID-19, and RSV.11142025Link
    Oncology Program FocusA peptide drug conjugate for gastrointestinal cancers.11142025Link
    Drug Development PlatformIMP3ACT Platform, which combines artificial intelligence (AI), machine learning (ML), and high-speed synthesis techniques.11142025Link
    Number of Investors91102026Link
    Next-Generation Discovery ProgramsMulti-virus decoy candidates for overlapping respiratory threats and validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates.1072026Link

    Price Chart

    null
    Upcoming
    11/13/2026Earnings ReleaseRev: -
    EPS: -

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 9/1/2026

    Decoy Therapeutics Inc. (DCOY) stock has lost about 70% since 5/31/2026 because of the following key factors:

    1. Significant widening of net loss and "going concern" warning in Q2 2026.

    Decoy Therapeutics Inc. reported a substantial widening of its net loss to $2,373,800 for fiscal Q2 2026, which ended June 30, 2026, compared to a net loss of $957,825 in the same quarter a year prior. The company's net loss for the first six months of 2026 totaled $4,598,428. Accompanying these results, management explicitly stated "substantial doubt about the company's ability to continue as a going concern," with existing cash expected to fund operations only into late 2026. This financial distress was a core reason for investor apprehension, leading to the stock falling about 7% around the Q2 earnings release on August 12, 2026.

    2. Dilutive financing and NASDAQ listing concerns amidst low cash reserves.

    In June 2026, Decoy Therapeutics completed a private placement that generated approximately $3.5 million in gross proceeds through the sale of 592,217 common shares (or pre-funded warrants) at $5.91 per share. While this provided a "critical lifeline," the ongoing need for financing and associated dilution weighed on the stock. Furthermore, the company's low market capitalization, which was around $1.90 million as of August 31, 2026, raised concerns about meeting a proposed NASDAQ $5 million market-value listing standard, adding to the negative sentiment.

    Show more
    Updated on 9/1/2026

    Decoy Therapeutics Inc. (DCOY) stock has lost about 70% since 5/31/2026 because of the following key factors:

    1. Significant widening of net loss and "going concern" warning in Q2 2026.

    Decoy Therapeutics Inc. reported a substantial widening of its net loss to $2,373,800 for fiscal Q2 2026, which ended June 30, 2026, compared to a net loss of $957,825 in the same quarter a year prior. The company's net loss for the first six months of 2026 totaled $4,598,428. Accompanying these results, management explicitly stated "substantial doubt about the company's ability to continue as a going concern," with existing cash expected to fund operations only into late 2026. This financial distress was a core reason for investor apprehension, leading to the stock falling about 7% around the Q2 earnings release on August 12, 2026.

    2. Dilutive financing and NASDAQ listing concerns amidst low cash reserves.

    In June 2026, Decoy Therapeutics completed a private placement that generated approximately $3.5 million in gross proceeds through the sale of 592,217 common shares (or pre-funded warrants) at $5.91 per share. While this provided a "critical lifeline," the ongoing need for financing and associated dilution weighed on the stock. Furthermore, the company's low market capitalization, which was around $1.90 million as of August 31, 2026, raised concerns about meeting a proposed NASDAQ $5 million market-value listing standard, adding to the negative sentiment.

    3. Persistent preclinical stage status and lack of product revenue.

    As a preclinical-stage biotechnology company, Decoy Therapeutics Inc. generated only $227,629 in grant revenue for fiscal Q2 2026 and continues to report no product revenue. This prolonged pre-revenue status, coupled with increasing research and development and general and administrative expenses contributing to widening losses, indicates a lack of immediate commercial prospects and elevated risk for investors in a sector where other companies were experiencing significant growth and M&A activity during the same period.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -70.1% change in DCOY stock from 5/31/2026 to 9/13/2026 was primarily driven by a -0.1% change in the company's Shares Outstanding (Mil).
    (LTM values as of)53120269132026Change
    Stock Price ($)8.922.67-70.1%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)11-0.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    5/31/2026 to 9/13/2026
    ReturnCorrelation
    DCOY-70.1% 
    Market (SPY)1.0%22.8%
    Sector (XLV)10.6%-3.9%

    Fundamental Drivers

    The -67.3% change in DCOY stock from 2/28/2026 to 9/13/2026 was primarily driven by a -92.5% change in the company's Shares Outstanding (Mil).
    (LTM values as of)22820269132026Change
    Stock Price ($)8.172.67-67.3%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)01-92.5%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    2/28/2026 to 9/13/2026
    ReturnCorrelation
    DCOY-67.3% 
    Market (SPY)11.7%19.4%
    Sector (XLV)3.6%5.0%

    Fundamental Drivers

    The -96.1% change in DCOY stock from 8/31/2025 to 9/13/2026 was primarily driven by a -97.8% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120259132026Change
    Stock Price ($)69.122.67-96.1%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)01-97.8%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2025 to 9/13/2026
    ReturnCorrelation
    DCOY-96.1% 
    Market (SPY)19.5%16.6%
    Sector (XLV)21.9%2.8%

    Fundamental Drivers

    The -99.8% change in DCOY stock from 8/31/2023 to 9/13/2026 was primarily driven by a -99.6% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120239132026Change
    Stock Price ($)1267.062.67-99.8%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)01-99.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2023 to 9/13/2026
    ReturnCorrelation
    DCOY-99.8% 
    Market (SPY)75.7%1.7%
    Sector (XLV)30.0%-3.1%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    DCOY Return-46%-88%-58%-65%-98%-65%-100%
    Peers Return-7%32%41%-1%13%10%111%
    S&P 500 Return27%-19%24%23%16%11%102%

    Monthly Win Rates [3]
    DCOY Win Rate25%17%25%33%33%22% 
    Peers Win Rate42%67%58%50%83%64% 
    S&P 500 Win Rate75%42%67%75%67%44% 

    Max Drawdowns [4]
    DCOY Max Drawdown-84%-92%-84%-78%-99%-82% 
    Peers Max Drawdown-27%-19%-12%-23%-29%-15% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: VRTX, APMD, ATTO, BLSM, BRVE.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 9/11/2026 (YTD)

    How Low Can It Go

    EventDCOYS&P 500
    2024 Yen Carry Trade Unwind
      % Loss-44.2%-7.8%
      % Gain to Breakeven79.2%8.5%
      Time to Breakeven8 days18 days
    2020 COVID-19 Crash
      % Loss-41.1%-33.7%
      % Gain to Breakeven69.8%50.9%
      Time to Breakeven56 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-50.0%-19.2%
      % Gain to Breakeven100.0%23.8%
      Time to Breakeven109 days105 days

    Compare to VRTX, APMD, ATTO, BLSM, BRVE

    In The Past

    Decoy Therapeutics Inc.'s stock fell -44.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 79.2% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventDCOYS&P 500
    2024 Yen Carry Trade Unwind
      % Loss-44.2%-7.8%
      % Gain to Breakeven79.2%8.5%
      Time to Breakeven8 days18 days
    2020 COVID-19 Crash
      % Loss-41.1%-33.7%
      % Gain to Breakeven69.8%50.9%
      Time to Breakeven56 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-50.0%-19.2%
      % Gain to Breakeven100.0%23.8%
      Time to Breakeven109 days105 days

    Compare to VRTX, APMD, ATTO, BLSM, BRVE

    In The Past

    Decoy Therapeutics Inc.'s stock fell -44.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 79.2% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Decoy Therapeutics Inc. (DCOY)

    Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    • Seclidemstat (SP-2577): A small molecular inhibitor undergoing Phase I/II clinical trials for advanced solid tumors and Ewing sarcoma.
    • SP-3164: A small molecular protein degrader developed for treating hematological and solid tumors.

    AI Analysis | Feedback

    Decoy Therapeutics Inc. (DCOY), as a clinical-stage biotechnology company, is primarily focused on the development of epigenetic-based cancer treatments. Its lead candidates, Seclidemstat (SP-2577) and SP-3164, are currently in Phase I/II clinical trials and have not yet received regulatory approval for commercial sale.

    Given that its drug candidates are still in the developmental and clinical trial stages, Decoy Therapeutics Inc. does not currently have major customers that purchase its therapeutic products. Its business model at this stage involves research, development, and strategic partnerships rather than commercial sales to individuals or other companies (such as hospitals, pharmacies, or distributors).

    Therefore, Decoy Therapeutics Inc. does not have major customers to list at this time.

    AI Analysis | Feedback

    HLB Life Sciences (079430)

    AI Analysis | Feedback

    Rick Pierce, Chief Executive Officer

    Mr. Pierce co-founded Decoy Therapeutics in 2020 and has served as its Chief Executive Officer and director since its inception. He has over 20 years of senior leadership and operating experience in building successful biotechnology companies. From September 2022 to November 2024, Mr. Pierce was an executive officer of Innovation1 Biotech, Inc., a drug discovery company. He also served as a Senior Advisor for Bionest Partners, a life sciences consulting company, from 2017 to 2020. Mr. Pierce is an advisor to the Canadian Consulate of Boston/Cambridge’s Healthcare and Technology Accelerator and a board member of the Canadian Entrepreneurs of New England, where he chairs the Life Sciences Leadership Council.

    Mark Rosenblum, Chief Financial Officer

    Mr. Rosenblum was the Chief Financial Officer of Salarius Pharmaceuticals and continued in this role for the combined company, Decoy Therapeutics, following the merger. He was also appointed as the acting Chief Executive Officer of Salarius Pharmaceuticals in August 2025 as the company finalized its merger with Decoy Therapeutics Inc. Prior to joining Salarius as a financial consultant to assist with a previous merger, Mr. Rosenblum served as Chairman and Chief Executive Officer of ActiveCare, Inc., a publicly traded healthcare company, and has held Chief Financial Officer positions at several publicly traded companies. He holds a Masters in Accountancy and a B.S.

    Barbara Hibner, Chief Scientific Officer

    Dr. Hibner co-founded Decoy Therapeutics in 2020 and has served as its Chief Scientific Officer, Director, and Board Chair since then. From January 2017 to April 2020, she co-founded and was Chief Executive Officer of PercepTx, a company focused on targeted cancer immunotherapy utilizing computational modeling and quantitative pharmacology for antibody drug conjugates. Before that, Dr. Hibner held various scientific and managerial roles in discovery, pharmacology, and research quality at Bayer. Her contributions include work that led to the approval of two small molecule drugs, sorafenib and ixazomib.

    Peter Marschel, Chief Business Officer

    Mr. Marschel co-founded Decoy Therapeutics in 2020 and has been its Chief Business Officer and director since then. Previously, until April 2020, he co-founded and served as Chief Financial Officer of PercepTx, a targeted cancer immunotherapy accelerator that focused on leveraging computational modeling and quantitative pharmacology to enhance the value of preclinical monoclonal antibody-based therapeutic assets. He holds an MSA and an MBA.

    Michael Lipp, Chief Technology Officer

    Dr. Lipp is a co-founder of Decoy Therapeutics. He holds a PhD.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    For Decoy Therapeutics Inc. (DCOY), previously Salarius Pharmaceuticals, Inc., the expected drivers of future revenue growth over the next 2-3 years are primarily centered on advancing its innovative peptide conjugate therapeutics platform and pipeline through strategic collaborations and funding, given its preclinical stage.

    1. Advancement of Pipeline Candidates through Strategic Partnerships: Decoy Therapeutics's focus on developing novel peptide conjugate therapeutics, particularly its lead antiviral programs targeting respiratory viruses like pan-coronavirus, flu, COVID-19, and RSV, and candidates for GI cancers, is a key driver. As these preclinical programs successfully advance into and through early clinical stages, the company is likely to secure milestone payments from existing or new strategic development partners.
    2. New Strategic Collaborations and Licensing Agreements: The company's proprietary IMP3ACT platform, which leverages machine learning and AI for designing and manufacturing peptide conjugates, presents a significant opportunity for revenue growth. Forming additional strategic partnerships or licensing agreements with larger pharmaceutical companies to co-develop specific drug candidates or to license the platform technology itself could generate upfront payments, research funding, and future milestone payments.
    3. Increased Non-Dilutive Funding and Grants: Decoy Therapeutics has already secured significant non-dilutive capital, including a Global Access Commitment Agreement with the Gates Foundation to fund the development of a globally accessible manufacturing platform for antiviral therapeutics, and funding support from Google AI startup program and NVIDIA Inception program. Continued and expanded non-dilutive funding from such foundations and governmental agencies like the Biomedical Advanced Research and Development Authority (BARDA) for its antiviral development efforts will contribute directly to its financial resources and R&D capabilities, impacting its revenue over the next 2-3 years.

    AI Analysis | Feedback

    Share Issuance

    • Decoy Therapeutics implemented a 1-for-12 reverse stock split effective March 6, 2026, reducing outstanding shares from approximately 6.38 million to 532,000, primarily to regain compliance with Nasdaq's minimum bid price requirement.
    • Shareholders approved the Decoy Therapeutics 2026 Equity Incentive Plan on February 25, 2026.
    • Shareholders have experienced substantial dilution over the past year, with total shares outstanding growing by 5442.4%, and the company previously conducted a 1-for-15 reverse stock split on August 18, 2025.

    Inbound Investments

    • Decoy Therapeutics entered into a Global Access Commitment Agreement with the Bill & Melinda Gates Foundation in January 2026 to develop a globally accessible manufacturing platform for peptide-conjugate antivirals.

    Capital Expenditures

    • Decoy Therapeutics has reported minimal or no significant capital expenditures in recent years, with some financial statements indicating $0 for certain periods.

    Peer Outperformance in Biotechnology

    DCOY has trailed 97% of its 361 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Biotechnology constituents that DCOY has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    3%
    of 455 industry peers · -95.8% return
    3Y
    4%
    of 401 industry peers · -99.8% return
    5Y
    3%
    of 361 industry peers · -100.0% return
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is DCOY's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 7 7.1%86.3%123.6% CAH 402% · MCK 343% · COR 175%
    Managed Health Care 8 43.7%-1.3%8.2% OSCR 84% · HQY 57% · ELV 23%
    Health Care Services 20 18.9%44.9%0.0% HIMS 218% · RDNT 172% · DGX 67%
    Health Care Facilities 24 3.7%7.9%-14.2% NHC 276% · THC 268% · ENSG 122%
    Health Care Equipment 50 -1.7%-5.5%-25.7% POCI 10800% · UFPT 331% · GKOS 234%
    Health Care Supplies 12 20.8%-12.1%-37.9% LNTH 308% · HAE 51% · MMSI 21%
    Pharmaceuticals 62 -7.4%7.7%-40.7% LQDA 2457% · INDV 1136% · ETON 1063%
    Life Sciences Tools & Services 109 -1.4%-25.5%-71.2% SNWV 1573% · MEDP 224% · NTRA 174%
    Health Care Technology 20 -31.7%-52.2%-78.5% SPOK 77% · HSTM 3% · VEEV -12%
    Biotechnology ← 362 1.6%-24.8%-79.6% DNTH 1632% · CELZ 1272% · ELVN 1222%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    ACVAACV Auctions1.855.4%29.8%
    FEIMFrequency Electronics0.947.6%64.1%
    SEISolaris Energy Infrastructure4.026.8%47.3%
    ASOAcademy Sports and Outdoors3.626.7%11.5%
    MXLMaxLinear6.725.4%327.8%
    AEHRAehr Test Systems3.024.2%369.0%
    COHUCohu2.724.1%145.3%
    SWKSSkyworks Solutions13.323.6%42.2%
    SMTCSemtech15.523.5%127.0%
    SIGSignet Jewelers4.022.2%22.3%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    TTANServiceTitan5.2-41.3%-48.7%
    ADBTAdvasa0.1-32.4%-96.3%
    GWREGuidewire Software11.9-30.5%-29.9%
    BRZEBraze2.7-28.0%-30.2%
    DYNDyne Therapeutics3.0-27.0%-6.9%
    SGMLSigma Lithium1.1-25.6%-28.0%
    TBBKBancorp2.1-25.3%-25.0%
    PATHUiPath7.2-24.5%-16.1%
    NAVNNavan5.3-24.1%23.1%
    COOCooper Companies10.5-23.7%-34.2%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MRNAModerna57.3126.1%388.2%
    CAPRCapricor Therapeutics0.599.8%-71.0%
    PURRHyperliquid Strategies1.472.0%226.1%
    HTFLHeartFlow4.367.1%71.1%
    AVAHAveanna Healthcare3.155.6%72.3%
    BTGOBitGo0.953.3%-58.6%
    FWDIForward Industries0.648.9%-0.9%
    ANGXAngel Studios1.048.1%16.7%
    WEAVWeave Communications0.645.9%-3.7%
    ARXAccelerant4.345.8%21.3%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    ALMSAlumis1.2-64.1%-5.9%
    RAREUltragenyx Pharmaceutical1.5-46.8%-37.8%
    IESCIES13.8-43.6%-11.1%
    KRMNKarman4.7-43.0%-51.8%
    TTANServiceTitan5.2-40.6%-48.7%
    CRDOCredo Technology30.1-39.2%13.2%
    AEVAAeva Technologies1.0-38.3%16.9%
    EVCMEverCommerce1.1-36.7%-47.9%
    AADXApplied Aerospace & Defense1.8-36.2%-35.8%
    BLZEBackblaze0.8-35.9%166.1%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    DCOYVRTXAPMDATTOBLSMBRVEMedian
    NameDecoy Th.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Mkt Price2.67515.4426.2322.7920.8626.6424.51
    Mkt Cap0.0130.8----65.4
    Rev LTM012,5871170-00
    Op Inc LTM-154,77723-74--31-15
    FCF LTM-83,796-84-64--25-25
    FCF 3Y Avg-71,957----975
    CFO LTM-84,293-84-62--22-22
    CFO 3Y Avg-72,398----1,196

    Growth & Margins

    DCOYVRTXAPMDATTOBLSMBRVEMedian
    NameDecoy Th.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Rev Chg LTM-10.2%----10.2%
    Rev Chg 3Y Avg-9.8%----9.8%
    Rev Chg Q-12.5%----12.5%
    QoQ Delta Rev Chg LTM-3.0%----3.0%
    Op Inc Chg LTM-182.2%2,497.9%----1,157.8%
    Op Inc Chg 3Y Avg-30.1%792.2%----381.1%
    Op Mgn LTM-37.9%19.9%-16,551.6%--19.9%
    Op Mgn 3Y Avg-23.9%----23.9%
    QoQ Delta Op Mgn LTM--0.2%-----0.2%
    CFO/Rev LTM-34.1%-71.5%-13,695.3%---71.5%
    CFO/Rev 3Y Avg-19.6%----19.6%
    FCF/Rev LTM-30.2%-71.5%-14,194.7%---71.5%
    FCF/Rev 3Y Avg-15.7%----15.7%

    Valuation

    DCOYVRTXAPMDATTOBLSMBRVEMedian
    NameDecoy Th.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Mkt Cap0.0130.8----65.4
    P/S-10.4----10.4
    P/Op Inc-0.127.4----13.6
    P/EBIT-0.125.9----12.9
    P/E-0.129.7----14.8
    P/CFO-0.230.5----15.1
    Total Yield-1,016.8%3.4%-----506.7%
    Dividend Yield0.0%0.0%----0.0%
    FCF Yield 3Y Avg-3,095.8%1.6%-----1,547.1%
    D/E0.00.0----0.0
    Net D/E-5.8-0.0-----2.9

    Returns

    DCOYVRTXAPMDATTOBLSMBRVEMedian
    NameDecoy Th.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    1M Rtn-25.4%1.9%-17.4%14.8%28.9%-1.4%0.2%
    3M Rtn-55.6%15.8%4.9%4.1%30.4%-10.6%4.5%
    6M Rtn-65.0%9.8%4.9%4.1%30.4%-10.6%4.5%
    12M Rtn-95.8%30.6%4.9%4.1%30.4%-10.6%4.5%
    3Y Rtn-99.8%47.5%4.9%4.1%30.4%-10.6%4.5%
    1M Excs Rtn-24.7%-0.8%-0.4%27.4%29.6%3.1%1.3%
    3M Excs Rtn-58.3%12.3%1.4%0.5%26.8%-14.2%0.9%
    6M Excs Rtn-79.1%-6.9%-9.8%-10.7%15.6%-25.4%-10.3%
    12M Excs Rtn-112.4%15.4%-12.3%-13.2%13.2%-27.8%-12.7%
    3Y Excs Rtn-171.3%-21.8%-66.6%-67.4%-41.1%-82.1%-67.0%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/12/20265/8/20263/31/202611/14/20258/12/20255/14/20253/21/202511/14/20248/9/20245/13/20243/22/202411/9/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-2-2-9-1-1-2-1-1-1-2-1-3
    Operating Income-2-2-9-1-1-2-1-1-1-2-1-3
    Net Income-2-2-9-1-1-2-1-1-1-2-1-2
    EPS-4.46-4.18-16.88-21.72-81.21-240.07-182.85-136.56-426.60-588.60-5.40-937.80
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-15-13-13-5-5-6-6-5-7-9-13-18
    Operating Income TTM-15-13-13-5-5-6-6-5-7-9-13-18
    Net Income TTM-14-13-13-5-5-6-6-5-6-9-13-18
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-147.8%-32.6%-507.1%11.1%34.2%3.0%-53.4%60.2%63.1%67.3%85.0%55.0%
    Operating Income Growth-148.9%-32.9%-506.9%11.1%34.2%3.0%-53.4%60.3%63.0%67.3%85.0%55.0%
    Net Income Growth-147.8%-30.1%-513.3%10.1%32.8%0.3%-66.0%60.2%63.3%67.9%86.2%83.0%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash8811512233468
    Total Debt000000000000
    Net Debt / (Cash)-8-8-11-5-1-2-2-3-3-4-6-7
    Cash Flows Quarterly            
    FCF from Operations-3-3-1-2-1-1-1-1-1-1-2-4
    Cash Flows TTM            
    FCF from Operations TTM-8-7-5-4-4-4-5-5-8-11-13-16
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-10.1%-9.9%-40.3%-4.2%-4.7%-8.4%-7.3%-5.0%-7.5%-9.1%-5.1%-13.6%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-15.4%-14.2%-14.1%-6.0%-6.2%-6.9%-7.1%-6.5%-8.6%-11.9%-17.0%-24.7%

    Segment Financials

    Revenue by Segment
    $ Mil20212020201920182017
    Developing treatments for cancers caused by dysregulated gene expression2531 
    Consumer Operations    1
    Corporate    0
    Drug Development    0
    Total25311


    Operating Income by Segment
    $ Mil20252024201820172016
    Developing treatments for cancers caused by dysregulated gene expression-13-6-2  
    Corporate  -8-9-10
    Drug Development  -12-17-20
    Consumer Operations   -9-10
    Total-13-6-22-35-40


    Net Income by Segment
    $ Mil202520242023
    Developing treatments for cancers caused by dysregulated gene expression-13-6-13
    Total-13-6-13


    Assets by Segment
    $ Mil202320222021
    Developing treatments for cancers caused by dysregulated gene expression71541
    Total71541


    Price Behavior

    Price Behavior
    Market Price$2.67 
    Market Cap ($ Bil)0.0 
    First Trading Date01/08/2026 
    Distance from 52W High-96.1% 
       50 Days200 Days
    DMA Price$4.21$6.83
    DMA Trenddowndown
    Distance from DMA-36.6%-60.9%
     3M1YR
    Volatility183.1%156.2%
    Downside Capture349.92308.20
    Upside Capture-99.89-118.65
    Correlation (SPY)25.5%16.1%
    DCOY Betas & Captures as of 8/31/2026

     1M2M3M6M1Y3Y
    Beta0.571.263.292.112.150.19
    Up Beta4.294.0711.594.334.16-1.12
    Down Beta-2.07-1.25-0.350.912.481.64
    Up Capture-285%-235%-114%5%-43%-6%
    Bmk +ve Days10213268138427
    Stock +ve Days7132452102309
    Down Capture238%430%297%207%182%109%
    Bmk -ve Days11213259113324
    Stock -ve Days14294074147428

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with DCOY
    DCOY-95.2%156.1%-1.20-
    Sector ETF (XLV)22.1%16.2%1.042.7%
    Equity (SPY)18.3%12.8%1.0316.8%
    Gold (GLD)19.0%29.2%0.59-2.6%
    Commodities (DBC)48.3%20.6%1.80-4.8%
    Real Estate (VNQ)7.6%13.6%0.293.0%
    Bitcoin (BTCUSD)-32.4%43.8%-0.7713.8%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with DCOY
    DCOY-85.2%146.8%-0.68-
    Sector ETF (XLV)5.5%15.2%0.181.5%
    Equity (SPY)12.5%17.2%0.554.7%
    Gold (GLD)18.7%18.8%0.81-3.1%
    Commodities (DBC)11.4%19.5%0.460.4%
    Real Estate (VNQ)0.7%18.9%-0.075.1%
    Bitcoin (BTCUSD)9.4%52.6%0.362.4%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with DCOY
    DCOY-84.1%135.8%-0.57-
    Sector ETF (XLV)10.4%16.7%0.507.0%
    Equity (SPY)15.2%17.9%0.729.0%
    Gold (GLD)12.3%16.3%0.62-1.6%
    Commodities (DBC)8.7%18.1%0.394.0%
    Real Estate (VNQ)4.7%20.7%0.199.3%
    Bitcoin (BTCUSD)63.2%66.2%1.034.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date8312026
    Short Interest: Shares Quantity0.0 Mil
    Short Interest: % Change Since 815202623.2%
    Average Daily Volume0.0 Mil
    Days-to-Cover Short Interest1
    Basic Shares Quantity0.5 Mil
    Short % of Basic Shares2.5%

    Earnings Returns History

    Updated 7/15/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/10/2023-5.9%27.6%22.0%
    11/10/20223.8%17.4%0.0%
    8/15/20222.2%-6.7%-8.2%
    5/12/2022-15.4%-11.2%-12.2%
    3/10/2022-26.6%-21.9%-25.7%
    8/5/20216.6%9.9%40.8%
    8/12/2020-4.7%-4.7%-21.2%
    SUMMARY STATS   
    # Positive333
    # Negative444
    Median Positive3.8%17.4%22.0%
    Median Negative-10.6%-8.9%-16.7%
    Max Positive6.6%27.6%40.8%
    Max Negative-26.6%-21.9%-25.7%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/10/2023-5.9%27.6%22.0%
    11/10/20223.8%17.4%0.0%
    8/15/20222.2%-6.7%-8.2%
    5/12/2022-15.4%-11.2%-12.2%
    3/10/2022-26.6%-21.9%-25.7%
    8/5/20216.6%9.9%40.8%
    8/12/2020-4.7%-4.7%-21.2%
    SUMMARY STATS   
    # Positive333
    # Negative444
    Median Positive3.8%17.4%22.0%
    Median Negative-10.6%-8.9%-16.7%
    Max Positive6.6%27.6%40.8%
    Max Negative-26.6%-21.9%-25.7%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/08/202610-Q
    12/31/202503/31/202610-K
    09/30/202511/14/202510-Q
    06/30/202508/12/202510-Q
    03/31/202505/14/202510-Q
    12/31/202403/21/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/09/202410-Q
    03/31/202405/13/202410-Q
    12/31/202303/22/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/10/202310-Q
    03/31/202305/11/202310-Q
    12/31/202203/27/202310-K
    09/30/202211/10/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/08/202610-Q
    12/31/202503/31/202610-K
    09/30/202511/14/202510-Q
    06/30/202508/12/202510-Q
    03/31/202505/14/202510-Q
    12/31/202403/21/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/09/202410-Q
    03/31/202405/13/202410-Q
    12/31/202303/22/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/10/202310-Q
    03/31/202305/11/202310-Q
    12/31/202203/27/202310-K
    09/30/202211/10/202210-Q
    06/30/202208/05/202210-Q
    03/31/202205/12/202210-Q
    12/31/202103/25/202210-K
    09/30/202111/04/202110-Q
    06/30/202108/05/202110-Q
    03/31/202105/12/202110-Q
    12/31/202003/18/202110-K
    09/30/202011/12/202010-Q
    06/30/202008/12/202010-Q
    03/31/202005/14/202010-Q
    12/31/201903/23/202010-K
    09/30/201911/12/201910-Q

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 9/13/2026